- Home
- BDTX vs GLSI Comparison
BDTX vs GLSI Comparison
Compare BDTX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- GLSI
- Stock Information
- Founded
- BDTX 2014
- GLSI 2006
- Country
- BDTX United States
- GLSI United States
- Employees
- BDTX N/A
- GLSI N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- GLSI Health Care
- Exchange
- BDTX Nasdaq
- GLSI Nasdaq
- Market Cap
- BDTX 181.4M
- GLSI 149.5M
- IPO Year
- BDTX 2020
- GLSI 2020
- Fundamental
- Price
- BDTX $2.94
- GLSI $10.93
- Analyst Decision
- BDTX Strong Buy
- GLSI Strong Buy
- Analyst Count
- BDTX 6
- GLSI 1
- Target Price
- BDTX $12.50
- GLSI $39.00
- AVG Volume (30 Days)
- BDTX 802.5K
- GLSI 43.1K
- Earning Date
- BDTX 11-04-2025
- GLSI 08-14-2025
- Dividend Yield
- BDTX N/A
- GLSI N/A
- EPS Growth
- BDTX N/A
- GLSI N/A
- EPS
- BDTX 0.25
- GLSI N/A
- Revenue
- BDTX $70,000,000.00
- GLSI N/A
- Revenue This Year
- BDTX N/A
- GLSI N/A
- Revenue Next Year
- BDTX N/A
- GLSI N/A
- P/E Ratio
- BDTX $11.74
- GLSI N/A
- Revenue Growth
- BDTX N/A
- GLSI N/A
- 52 Week Low
- BDTX $1.20
- GLSI $8.06
- 52 Week High
- BDTX $6.33
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- BDTX 57.58
- GLSI 41.04
- Support Level
- BDTX $2.56
- GLSI $10.87
- Resistance Level
- BDTX $2.95
- GLSI $11.89
- Average True Range (ATR)
- BDTX 0.16
- GLSI 0.54
- MACD
- BDTX 0.02
- GLSI -0.16
- Stochastic Oscillator
- BDTX 79.00
- GLSI 3.95
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.